| Identification | |
| Name: | Ibandronate sodium monohydrate |
| Synonyms: | Phosphonicacid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-, monosodium salt,monohydrate (9CI);BM 21.0955Na.H2O;BM 21.0955 . Na . H2O;Monosodiumibandronate monohydrate;Sodium trihydrogen (1-hydroxy-3-(methylpentylamino)propylidene)diphosphonate, monohydrate; |
| CAS: | 138926-19-9 |
| Molecular Formula: | C9H24NNaO8P2 |
| Molecular Weight: | 341.21 |
| InChI: | InChI=1/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1 |
| Molecular Structure: | ![(C9H24NNaO8P2) Phosphonicacid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-, monosodium salt,monohydrate (9CI);...](https://img.guidechem.com/casimg/138926-19-9.gif) |
| Properties | |
| Density: | == |
| Appearance: | White Crystalline Powder |
| Specification: |
?Ibandronate sodium?,?its cas register number is 138926-19-9. It also can be called?Ibandronate sodium monohydrate ; Sodium trihydrogen (1-hydroxy-3- |
| Usage: | Inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active. Biphosphonates are used in disorders affecting the skeleton such as asteoporosis, metastatic disease, and Paget d |
| Safety Data | |
| Hazard Symbols |
Xn: Harmful
|
 |
|
